What is the primary strategic rationale behind Ipsen's acquisition of Kartos Therapeutics?

The primary strategic rationale is to expand Ipsen's oncology pipeline with navtemadlin, an investigational oral therapy in Phase III development for myelofibrosis—a rare blood cancer.

What are the key financial terms of the Ipsen–Kartos deal, including upfront payment and potential additional compensation?

Ipsen will pay $450 million upfront to acquire Kartos Therapeutics, and Kartos shareholders are eligible for up to $1.3 billion in additional milestone payments tied to regulatory approvals and sales targets.

French Biotech Company Ipsen to Buy Kartos Therapeutics for $450 Million

Jun 29, 2026

French biotech firm Ipsen agreed to acquire U.S.-based Kartos Therapeutics for $450 million to expand its oncology pipeline with late-stage blood cancer treatment navtemadlin. The transaction includes potential milestone payments and is expected to close by Q3.

reuters

2026-06-29

French Biotech Company Ipsen to Buy Kartos Therapeutics for $450 Million

French Biotech Company Ipsen to Buy Kartos Therapeutics for $450 Million

FAQ